|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Competition
The pharmaceutical industry is highly competitive. Our principal
pharmaceutical competitors consist of major international
companies, many of which are larger and have greater financial
resources, technical staff, manufacturing, R&D and
marketing capabilities than we have. We also compete with
smaller research companies and generic drug manufacturers.
Tysabri, a treatment for relapsing forms of MS, competes
primarily with
Avonex®
marketed by our collaborator Biogen Idec,
Betaseron®
marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in
the United States and sold under the name
Betaferon®
by Bayer Schering Pharma in Europe,
Rebif®
marketed by Merck Serono and Pfizer Inc. in the United States
and by Merck Serono in Europe, and
Copaxone®
marketed by Teva Neurosciences, Inc. in the United States and
co-promoted by Teva and Sanofi-Aventis in Europe. Many companies
are working to develop new therapies or alternative formulations
of products for MS that if successfully developed would compete
with Tysabri.
A drug may be subject to competition from alternative therapies
during the period of patent protection or regulatory exclusivity
and, thereafter, it may be subject to further competition from
generic products. Our product Azactam lost its basic
U.S. patent protection in October 2005, and the basic
U.S. patent for Maxipime expired in March 2007.
Generic competitors have challenged existing patent protection
for some of the products from which we earn manufacturing or
royalty revenue. If these challenges are successful, our
manufacturing and royalty revenue will be materially and
adversely affected.
Governmental and other pressures toward the dispensing of
generic products may rapidly and significantly reduce, slow or
reverse the growth in, sales and profitability of any of our
products not protected by patents or regulatory exclusivity, and
may adversely affect our future results and financial condition.
The launch of competitive products, including generic versions
of our products, has had and may have a material adverse effect
on our revenues and results of operations.
Our competitive position depends, in part, upon our continuing
ability to discover, acquire and develop innovative,
cost-effective new products, as well as new indications and
product improvements protected by patents and other intellectual
property rights. We also compete on the basis of price and
product differentiation and through our sales and marketing
organization that provides information to medical professionals
and launches new products. If we fail to maintain our
competitive position, our business, financial condition and
results of operations may be materially and adversely affected.
Table of Contents
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Competition
The pharmaceutical industry is highly competitive. Our principal
pharmaceutical competitors consist of major international
companies, many of which are larger and have greater financial
resources, technical staff, manufacturing, R&D and
marketing capabilities than we have. We also compete with
smaller research companies and generic drug manufacturers.
Tysabri, a treatment for relapsing forms of MS, competes
primarily with
Avonex®
marketed by our collaborator Biogen Idec,
Betaseron®
marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in
the United States and sold under the name
Betaferon®
by Bayer Schering Pharma in Europe,
Rebif®
marketed by Merck Serono and
Table of Contents
Pfizer Inc. (Pfizer) in the United States and by Merck Serono in
Europe, and
Copaxone®
marketed by Teva Neurosciences, Inc. (Teva) in the United States
and co-promoted by Teva and Sanofi-Aventis in Europe. Many
companies are working to develop new therapies or alternative
formulations of products for MS, which if successfully developed
would compete with Tysabri.
A drug may be subject to competition from alternative therapies
during the period of patent protection or regulatory exclusivity
and, thereafter, it may be subject to further competition from
generic products. Our product Azactam lost its basic
U.S. patent protection in October 2005, and the basic
U.S. patent for Maxipime expired in March 2007.
Generic competitors have challenged existing patent protection
for some of the products from which we earn manufacturing or
royalty revenue. If these challenges are successful, our
manufacturing and royalty revenue will be materially and
adversely affected.
Governmental and other pressures toward the dispensing of
generic products may rapidly and significantly reduce, slow or
reverse the growth in, sales and profitability of any of our
products not protected by patents or regulatory exclusivity, and
may adversely affect our future results and financial condition.
The launch of competitive products, including generic versions
of our products, has had and may have a material adverse effect
on our revenues and results of operations.
Our competitive position depends, in part, upon our continuing
ability to discover, acquire and develop innovative,
cost-effective new products, as well as new indications and
product improvements protected by patents and other intellectual
property rights. We also compete on the basis of price and
product differentiation and through our sales and marketing
organization that provides information to medical professionals
and launches new products. If we fail to maintain our
competitive position, our business, financial condition and
results of operations may be materially adversely affected.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Competition
The pharmaceutical industry is highly competitive. Our principal
pharmaceutical competitors consist of major international
companies, many of which are larger and have greater financial
resources, technical staff, manufacturing, R&D and marketing
capabilities than us. We also compete with smaller research
companies and generic drug manufacturers.
Tysabri, a treatment for relapsing forms of MS, competes
primarily with
Avonex®
marketed by our collaborator Biogen Idec;
Betaseron®
marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in
the United States and sold under the name
Betaferon®
by Bayer Schering Pharma in Europe;
Rebif®
marketed by Merck Serono and Pfizer in the United States and by
Merck Serono in Europe; and
Copaxone®
marketed by Teva Neurosciences, Inc. (Teva) in the United States
and co-promoted by Teva and Sanofi-Aventis in Europe. Many
companies are working to develop new therapies or alternative
formulations of products for MS, which if successfully developed
would compete with Tysabri.
A drug may be subject to competition from alternative therapies
during the period of patent protection or regulatory exclusivity
and, thereafter, it may be subject to further competition from
generic products. Our product Azactam lost its basic US
patent protection in October 2005. We expect that generic
competition to Azactam will emerge in 2007 and will have
a material and adverse effect on our sales of
Azactam. The basic US patent for Maxipime
expires in March 2007. However, two US patents covering
Maxipime formulations may provide patent protection until
February 2008. When a generic competitor for Maxipime
enters the market, it will have a material and adverse
effect on our sales of Maxipime.
Generic competitors may also challenge existing patent
protection or regulatory exclusivity. Governmental and other
pressures toward the dispensing of generic products may rapidly
and significantly reduce, slow, or reverse the growth in, sales
and profitability of any of our products not protected by
patents or regulatory exclusivity, and may adversely affect our
future results and financial condition. The launch of competitor
products, including generic versions of our products, may
materially adversely affect our business, financial condition
and results of operations.
Our competitive position depends, in part, upon our continuing
ability to discover, acquire and develop innovative,
cost-effective new products, as well as new indications and
product improvements protected by patents and other intellectual
property rights. We also compete on the basis of price and
product differentiation and through our sales and marketing
organization that provides information to medical professionals
and launches new products. If we fail to maintain our
competitive position, our business, financial condition and
results of operations may be materially adversely affected.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Competition
The pharmaceutical industry is highly competitive. Our principal
pharmaceutical competitors consist of major international
companies, many of which are larger and have greater financial
resources, technical staff, manufacturing, R&D and marketing
capabilities than us. We also compete with smaller research
companies and generic drug manufacturers.
When Tysabri is reintroduced in the United States as a
treatment for relapsing forms of MS, it will compete primarily
with Avonex marketed by our collaborator Biogen Idec;
Betaseron®
marketed by Berlex Laboratories;
Rebif®
marketed by Serono SA and Pfizer; and
Copaxone®
marketed by Teva Pharmaceuticals Ltd. Many companies are working
to develop new therapies or alternative formulations of products
for MS, which if successfully developed would compete with
Tysabri. A drug may be subject to competition from
alternative therapies during the period of patent protection or
regulatory exclusivity and, thereafter, it may be subject to
further competition from generic products. Our product
Azactam lost its basic U.S. patent protection in
October 2005. We expect that generic competition to Azactam
will emerge in 2006 and will have a material and adverse
effect on sales of Azactam.
Generic competitors may also challenge existing patent
protection or regulatory exclusivity. Governmental and other
pressures toward the dispensing of generic products may rapidly
and significantly reduce, slow, or reverse the growth in, sales
and profitability of any of our products not protected by
patents or regulatory exclusivity, and may adversely affect our
future results and financial condition. The launch of competitor
products, including generic versions of our products, may
materially adversely affect our business, financial condition
and results of operations.
Our competitive position depends, in part, upon our continuing
ability to discover, acquire and develop innovative,
cost-effective new products, as well as new indications and
product improvements protected by patents and other intellectual
property rights. We also compete on the basis of price and
product differentiation and through our sales and marketing
organization that provides information to medical professionals
and launches new products. If we fail to maintain our
competitive position, our business, financial condition and
results of operations may be materially adversely affected.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
